-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
How Many Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares Do Institutions Own?
How Many Shandong Xinhua Pharmaceutical Company Limited (HKG:719) Shares Do Institutions Own?
The big shareholder groups in Shandong Xinhua Pharmaceutical Company Limited (HKG:719) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. We also tend to see lower insider ownership in companies that were previously publicly owned.
With a market capitalization of HK$11b, Shandong Xinhua Pharmaceutical is a decent size, so it is probably on the radar of institutional investors. Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. Let's take a closer look to see what the different types of shareholders can tell us about Shandong Xinhua Pharmaceutical.
See our latest analysis for Shandong Xinhua Pharmaceutical
SEHK:719 Ownership Breakdown August 4th 2022What Does The Institutional Ownership Tell Us About Shandong Xinhua Pharmaceutical?
Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.
As you can see, institutional investors have a fair amount of stake in Shandong Xinhua Pharmaceutical. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Shandong Xinhua Pharmaceutical's historic earnings and revenue below, but keep in mind there's always more to the story.
SEHK:719 Earnings and Revenue Growth August 4th 2022Shandong Xinhua Pharmaceutical is not owned by hedge funds. Our data shows that Hualu Holdings Co.,ltd. is the largest shareholder with 37% of shares outstanding. Hong Kong Exchanges and Clearing Limited is the second largest shareholder owning 29% of common stock, and Shanghai Chitai Asset Management Co., Ltd. holds about 4.1% of the company stock.
To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.
While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. As far as we can tell there isn't analyst coverage of the company, so it is probably flying under the radar.
Insider Ownership Of Shandong Xinhua Pharmaceutical
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
We can see that insiders own shares in Shandong Xinhua Pharmaceutical Company Limited. The insiders have a meaningful stake worth HK$127m. Most would see this as a real positive. It is good to see this level of investment by insiders. You can check here to see if those insiders have been buying recently.
General Public Ownership
The general public, who are usually individual investors, hold a 24% stake in Shandong Xinhua Pharmaceutical. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
Private Company Ownership
We can see that Private Companies own 37%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
Public Company Ownership
We can see that public companies hold 29% of the Shandong Xinhua Pharmaceutical shares on issue. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.
Next Steps:
It's always worth thinking about the different groups who own shares in a company. But to understand Shandong Xinhua Pharmaceutical better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Shandong Xinhua Pharmaceutical , and understanding them should be part of your investment process.
Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
山東新華藥業股份有限公司(HKG:719)的大股東集團對該公司擁有控制權。一般來説,隨着公司的成長,機構會增加他們的持股。相反,隨着時間的推移,內部人士往往會減少他們的持股。我們還傾向於看到,以前為公眾所有的公司的內部人持股比例較低。
山東新華醫藥的市值為110億港元,規模相當可觀,因此很可能在機構投資者的雷達上。我們對該公司所有權的分析顯示,機構投資者買入了該公司的股票。讓我們仔細看看不同類型的股東能告訴我們關於山東新華藥業的什麼。
查看我們對山東新華藥業的最新分析
聯交所:719所有權分類2022年8月4日關於山東新華藥業,機構持股告訴了我們什麼?
許多機構以一個接近當地市場的指數來衡量它們的表現。因此,他們通常更關注那些被納入主要指數的公司。
如你所見,機構投資者在山東新華藥業持有相當數量的股份。這表明在專業投資者中有一定的可信度。但我們不能僅僅依靠這一事實,因為機構有時會做出糟糕的投資,就像每個人一樣。當多家機構持有一隻股票時,它們總是面臨“擁擠交易”的風險。當這樣的交易出錯時,多方可能會競相快速拋售股票。在一家沒有增長曆史的公司,這一風險更高。你可以在下面看到山東新華醫藥的歷史收益和營收,但請記住,故事中總是有更多的內容。
聯交所:719盈利及收入增長2022年8月4日山東新華藥業並非由對衝基金所有。我們的數據顯示,華錄控股有限公司。是最大的股東,擁有37%的流通股。香港交易所有限公司是第二大股東,持有29%的普通股,上海奇泰資產管理有限公司持有公司約4.1%的股份。
為了讓我們的研究更有趣,我們發現,前兩名股東擁有公司的多數股權,這意味着他們足夠強大,可以影響公司的決策。
雖然研究一家公司的機構持股可以增加你的研究價值,但研究分析師的建議以更深入地瞭解一隻股票的預期表現也是一個很好的做法。據我們所知,沒有分析師對該公司的報道,所以它很可能在雷達下飛行。
山東新華醫藥的內部人所有權
儘管對內部人的準確定義可能是主觀的,但幾乎每個人都認為董事會成員是內部人。公司管理層對董事會負責,董事會應代表股東的利益。值得注意的是,有時最高層管理人員本身也是董事會成員。
大多數人認為內部人持股是積極的,因為它可以表明董事會與其他股東很好地結盟。然而,在某些情況下,太多的權力集中在這個羣體中。
我們可以看到,內部人士持有山東新華藥業有限公司的股份。這些內部人士持有價值1.27億港元的可觀股份。大多數人會認為這是一個真正的積極因素。看到內部人士的投資達到這樣的水平是件好事。你可以在這裏查看這些內部人士最近是否一直在買入。
一般公有制
一般公眾通常是個人投資者,他們持有山東新華醫藥24%的股份。雖然這羣人不一定能發號施令,但它肯定能對公司的運營方式產生真正的影響。
私營公司所有權
我們可以看到,私營公司擁有37%的已發行股份。或許有必要對此進行更深入的研究。如果關聯方,如內部人士,對這些私營公司中的一家有利害關係,則應在年報中披露。私營公司也可能對該公司擁有戰略利益。
上市公司所有權
我們可以看到,上市公司持有山東新華醫藥29%的已發行股份。我們不能確定,但很有可能這是一個戰略利益攸關方。這些業務可能是相似的,也可能是合作的。
接下來的步驟:
擁有一家公司股票的不同集團總是值得考慮的。但要更好地瞭解山東新華藥業,我們還需要考慮許多其他因素。例如,考慮一下無處不在的投資風險幽靈。我們已經確定了三個警告信號與山東新華藥業合作,瞭解他們應該是你投資過程的一部分。
當然了這可能不是最值得購買的股票。。所以讓我們來看看這個免費 免費有趣的公司名單。
注:本文中的數字是使用過去12個月的數據計算的,指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧